SecBot SecBot
8-K ·Filed Jun 10, 2026

VIR

Vir Biotechnology, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001628280-26-042237
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine board refresh with no operational or financial implications. No actionable trading signal; monitor upcoming quarterly filings for any strategic shifts.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.52
T+0 close · Jun 10, 2026 · via day close
Latest settled
+31.22%
T+60 · $11.18
Vs SPY
+27.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $8.52entry
  2. T+1 · 5mo ago +1.06%α +0.52% · $8.61
  3. T+5 · 5mo ago +9.15%α +8.72% · $9.30
  4. T+20 · 4mo ago +21.36%α +19.47% · $10.34
  5. T+60 · 2mo ago +31.22%α +27.40% · $11.18
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vir Biotechnology appointed Timothy Coughlin, CPA, as a new Class III director and Audit Committee Chair, expanding the board from 7 to 8 members. This is a routine governance change with no financial impact or strategic implications disclosed.

Key Facts

  • Board expanded from 7 to 8 members; Timothy Coughlin appointed to fill new vacancy
  • Coughlin will serve as Class III director until 2028 annual meeting and as Audit Committee Chair
  • No arrangement or understanding with any person triggered the appointment; no related party transactions
  • Coughlin receives standard non-employee director compensation per existing policy, including stock option and RSU grants under the 2019 Equity Incentive Plan

Financial Impact

Standard director compensation; no material financial impact disclosed

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-042237
Document: 0001628280-26-042237-index-headers.html0001628280-26-042237
Document: 0001628280-26-042237-index.html0001628280-26-042237
Document: 0001628280-26-042237.txt0001628280-26-042237

Track record

36 reports on VIR

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026